A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Cost-effectiveness of interferon in chronic myeloid leukaemia: Analysis of four clinical studies
1998
Annals of Oncology
Analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with one another in terms of cost per life-year saved. In patients with chronic myeloid leukaemia in chronic phase, long-term treatment with a-interferon has been reported to improve survival in comparison with standard treatments with cytotoxic drugs. To assess the pharmacoeconomic profile of interferon treatment in terms of cost per life-year gained,
doi:10.1023/a:1008212411489
pmid:9636829
fatcat:fx5whezz2jan5lc56vpfgsr3su